Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Kane GI, Diaz-Infante MB, Wigglesworth K, Lusi E, Brassil M, Rozen EJ, Kady J, Mori H, Lukas J, Naylor T, Dinnell RW, Murphy KC, Alarcon CBB, Ruscetti M, Brehm M, Shohet JM, Atukorale PU. Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma. Mol Cancer Ther. 2026 Jul 02; 25(7):1144-1156.
-
Khanduja S, Raman V, Hall CL, Howell LM, Van Dessel N, Forbes NS. Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory. Cell Rep Med. 2026 Jun 16; 7(6):102839.
-
Cui W, Xiao H, Wen X, Li C, Bao S, Long Y, Yang X, Wang K, Guo Q, Huang J. CEMs-SELEX: DNAzyme-powered de novo biomarker discovery and noninvasive cancer diagnosis. Sci Adv. 2026 May 29; 12(22):eaee7184.
-
Jamroze A, Liu X, Hou S, Jess Li W, Yu H, Tracz A, Jacobi J, Li Q, Nastiuk K, Chen X, Huang J, Lin K, Liu M, Cai C, Lu Y, Puzanov I, Kirk JS, Chatta G, Tang DG. Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. Signal Transduct Target Ther. 2026 May 01; 11(1).
-
Porto SA, Birdsall GA, Harper NW, Honeywell ME, Leighow SM, Naylor TE, Ward KM, Wesley MK, Pritchard JR, Lee MJ. Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibition. J Biol Chem. 2026 May; 302(5):111414.
-
Cui W, Xiao H, Wen X, Li C, Bao S, Zeng J, Li Y, Qiao Y, Wang K, Wang H, Huang J, Guo Q. Identifying a cancer therapeutic target: Cell-SELEX identifies a membrane protein for aptamer-mediated growth suppression. Proc Natl Acad Sci U S A. 2026 Mar 31; 123(13):e2514681123.
-
Ferro AP, Mensah SK, Liu YR, Guirro ECO, Celli JP. Photobiomodulation pre-treatment enhances ALA-induced PpIX accumulation and photodynamic therapy response in oral squamous cell carcinoma cells in cell culture. Photodiagnosis Photodyn Ther. 2026 Apr; 58:105433.
-
Fernando W, Clucas J, Rizzo A, Singer R, Goode E, Tiu C, Layzell S, Konecnik J, Wilson R, Wicky John S, Jouny S, Guppy N, Boulat V, Mannion J, Goicoechea M, Tan S, Lawson S, Starling C, Elshtein G, Ravindran N, Montgomery AB, Andres-Ejarque R, Allen M, Lumbard S, Wallberg F, Betteridge K, Scrimgeour R, Robertson D, Ward G, Sims M, Smyth T, Samson AL, Murphy JM, Kolarevic Ivankovic D, Arwert EN, Calado DP, Grigoriadis A, Smalley MJ, Melcher A, Haider S, Lawrence T, Roxanis I, Tutt ANJ, Tenev T, Meier P. Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy. Nat Commun. 2026 Mar 06; 17(1).
-
Qu W, Jia J, Zhang N, Wang R, Liu Y, Zhang S, Gao H, Tao Y, Jia L, Liu Y, Zhao J. Oncogenic role of PHF23 in gastric cancer progression. Funct Integr Genomics. 2026 Mar 04; 26(1).
-
Yu JX, Suh JM, Popova KD, Garcia K, Joshi T, Culbertson B, Spinelli JB, Subramanyam V, Lou K, Charbonneau T, Shokat KM, Weissman J, Goodarzi H. The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations. Nat Cancer. 2026 Mar; 7(3):522-537.